Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

This phase 3 trial evaluated the efficacy and safety of lenvatinib (a multitargeted tyrosine kinase inhibitor) plus pembrolizumab (a PD-1 inhibitor) versus chemotherapy (doxorubicin or paclitaxel) in patients with advanced endometrial cancer who had progressed after platinum-based chemotherapy. Among 827 randomized patients (697 with mismatch repair–proficient [pMMR] disease), lenvatinib–pembrolizumab significantly improved median progression-free survival (pMMR: 6.6 vs. 3.8 months; hazard ratio [HR] 0.60; P<0.001) and overall survival (pMMR: 17.4 vs. 12.0 months; HR 0.68; P<0.001). Similar benefits were observed in the overall population. Grade ≥3 adverse events occurred in 88.9% of the combination group versus 72.7% with chemotherapy. The study concludes that lenvatinib–pembrolizumab represents a new standard of care for this patient population.

This phase 3 trial evaluated the efficacy and safety of lenvatinib (a multitargeted tyrosine kinase inhibitor) plus pembrolizumab (a PD-1 inhibitor) versus chemotherapy (doxorubicin or paclitaxel) in patients with advanced endometrial cancer who had progressed after platinum-based chemotherapy. Among 827 randomized patients (697 with mismatch repair–proficient [pMMR] disease), lenvatinib–pembrolizumab significantly improved median progression-free survival (pMMR: 6.6 vs. 3.8 months; hazard ratio [HR] 0.60; P<0.001) and overall survival (pMMR: 17.4 vs. 12.0 months; HR 0.68; P<0.001). Similar benefits were observed in the overall population. Grade ≥3 adverse events occurred in 88.9% of the combination group versus 72.7% with chemotherapy. The study concludes that lenvatinib–pembrolizumab represents a new standard of care for this patient population.